Aevi Genomic Medicine Inc (GNMX) Director Sol J. Barer Acquires 2,551,020 Shares
Aevi Genomic Medicine Inc (NASDAQ:GNMX) Director Sol J. Barer acquired 2,551,020 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $0.96 per share, with a total value of $2,448,979.20. Following the completion of the transaction, the director now owns 1,028,032 shares of the company’s stock, valued at approximately $986,910.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Aevi Genomic Medicine stock opened at $1.16 on Friday. Aevi Genomic Medicine Inc has a 12-month low of $0.83 and a 12-month high of $2.65. The stock has a market cap of $58.15 million, a P/E ratio of -1.40 and a beta of 0.90.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. analysts predict that Aevi Genomic Medicine Inc will post -0.6 EPS for the current year.
A number of hedge funds have recently made changes to their positions in the business. Wedbush Securities Inc. purchased a new position in Aevi Genomic Medicine during the second quarter worth about $233,000. JPMorgan Chase & Co. boosted its stake in Aevi Genomic Medicine by 4,715.1% during the first quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after buying an additional 99,018 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Aevi Genomic Medicine by 515.8% during the fourth quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after buying an additional 78,400 shares during the period. 23.14% of the stock is owned by institutional investors.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Recommended Story: Diversification in Investing
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.